News | December 04, 2006

SCAI Abstract Deadline Extended

The Society for Cardiac Angiography and Interventions (SCAI) has extended the abstract deadline for its 30th Annual Scientific Sessions in Orlando, May 9-12, 2007. The new deadline is December 22, 2006 at midnight (EST).

The top three abstracts will received awards, and the top 10 abstracts selected will be featured for oral presentantion. All accepted abstracts will be published in the May 2007 edition of SCAI's Journal, “Catheterization and Cardiovascular Interventions.”

Abstract categories are:
-Acute Coronary Syndromes and Myocardial Infarction
-Adult Congenital
-Atherectomy/Plaque Modification
-Angiogenesis, Myogenesis, Cell Therapy and Gene Therapy
-Carotid Revascularization
-Complex PCI
-Contrast agents
-CTO
-Drug-Eluting Stents
-Endovascular & Peripheral Interventions (Excluding Neurovascular Intervention)
-Imaging: CT & MR
-Intravascular Imaging/Physiology
-Left Main & Multi-Vessel Intervention
-Interventions for Myocardial Infarction
-Miscellaneous
-Neurovascular, Carotid & Stroke Intervention
-Non-Invasive Imaging
-Pediatric
-Pharmacotherapy
-PTCA
-Restenosis
-Stents
-Thrombectomy and Distal Protection Devices
-Valvular Interventions
-Vascular Access & Arterial Closure Devices
-Vulnerable Plaque
-Women's Healthcare

For more information or to submit an abstract, visit www.scai.org.

Related Content

Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Overlay Init